What is HC Wainwright’s Forecast for BTAI Q1 Earnings?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of BioXcel Therapeutics in a research note issued to investors on Thursday, April 2nd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.31) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($24.39) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.26) EPS and Q4 2027 earnings at ($0.26) EPS.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its quarterly earnings results on Friday, March 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.58). The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.15 million.

Several other research analysts also recently commented on the stock. Zacks Research raised shares of BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, March 9th. Rodman & Renshaw initiated coverage on shares of BioXcel Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating and a $17.00 price target for the company. Wall Street Zen raised shares of BioXcel Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $11.00.

BioXcel Therapeutics Stock Performance

NASDAQ:BTAI opened at $1.18 on Friday. BioXcel Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $8.08. The firm has a market cap of $31.95 million, a PE ratio of -0.18 and a beta of 0.30. The business has a 50 day moving average price of $1.56 and a 200-day moving average price of $1.93.

Institutional Trading of BioXcel Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new stake in BioXcel Therapeutics in the third quarter valued at $2,632,000. Oaktree Capital Management LP purchased a new stake in shares of BioXcel Therapeutics in the 2nd quarter worth about $437,000. Jane Street Group LLC purchased a new stake in shares of BioXcel Therapeutics in the 4th quarter worth about $204,000. Geode Capital Management LLC boosted its stake in shares of BioXcel Therapeutics by 64.6% during the 4th quarter. Geode Capital Management LLC now owns 206,168 shares of the company’s stock valued at $330,000 after purchasing an additional 80,928 shares in the last quarter. Finally, Man Group plc purchased a new position in shares of BioXcel Therapeutics during the fourth quarter valued at about $91,000. Hedge funds and other institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.